Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Enantiomeric 4'-Truncated 3-deaza-1',6'-isoneplanocins: Synthesis and antiviral properties including Ebola.

Liu C, Coleman R, Archer A, Hussein I, Bowlin TL, Chen Q, Schneller SW.

Bioorg Med Chem Lett. 2019 Sep 1;29(17):2480-2482. doi: 10.1016/j.bmcl.2019.07.021. Epub 2019 Jul 11.

PMID:
31358469
2.

Activation of 6-Alkoxy-Substituted Methylenecyclopropane Nucleoside Analogs Requires Enzymatic Modification by Adenosine Deaminase-Like Protein 1.

Vollmer KJ, Burns AC, Sauer HE, Williams JD, Komazin-Meredith G, Cardinale S, Butler M, Aron Z, Hussein I, Busch MG, Bowlin TL, Gentry BG.

Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e01301-19. doi: 10.1128/AAC.01301-19. Print 2019 Oct.

PMID:
31332074
3.

Phase Ib Trial To Evaluate the Safety and Pharmacokinetics of Multiple Ascending Doses of Filociclovir (MBX-400, Cyclopropavir) in Healthy Volunteers.

Rouphael NG, Hurwitz SJ, Hart M, Beck A, Anderson EJ, Deye G, Osborn B, Cai SY, Focht C, Amegashie C, Bowlin TL, Brooks J, Mulligan MJ.

Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: e00717-19. doi: 10.1128/AAC.00717-19. Print 2019 Sep.

PMID:
31285228
4.

Aminomethyl spectinomycins: a novel antibacterial chemotype for biothreat pathogens.

Scarff JM, Waidyarachchi SL, Meyer CJ, Lane DJ, Chai W, Lemmon MM, Liu J, Butler MM, Bowlin TL, Lee RE, Panchal RG.

J Antibiot (Tokyo). 2019 Sep;72(9):693-701. doi: 10.1038/s41429-019-0194-8. Epub 2019 Jun 4.

5.

Efficacy of Aminomethyl Spectinomycins against Complex Upper Respiratory Tract Bacterial Infections.

Iverson A, Meyer CJ, Vogel P, Waidyarachchi S, Das N, Bruhn DF, Poole A, Butler MM, Bowlin TL, Lee RE, Rosch JW.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02096-18. doi: 10.1128/AAC.02096-18. Print 2019 May.

PMID:
30858215
6.

6'-Fluoro-3-deazaneplanocin: Synthesis and antiviral properties, including Ebola.

Liu C, Chen Q, Cardinale S, Bowlin TL, Schneller SW.

Bioorg Med Chem Lett. 2018 Dec 15;28(23-24):3674-3675. doi: 10.1016/j.bmcl.2018.10.030. Epub 2018 Oct 22.

PMID:
30385162
7.

A standardized approach to the evaluation of antivirals against DNA viruses: Polyomaviruses and lymphotropic herpesviruses.

Keith KA, Hartline CB, Bowlin TL, Prichard MN.

Antiviral Res. 2018 Nov;159:122-129. doi: 10.1016/j.antiviral.2018.09.016. Epub 2018 Oct 1.

PMID:
30287227
8.

A standardized approach to the evaluation of antivirals against DNA viruses: Orthopox-, adeno-, and herpesviruses.

Hartline CB, Keith KA, Eagar J, Harden EA, Bowlin TL, Prichard MN.

Antiviral Res. 2018 Nov;159:104-112. doi: 10.1016/j.antiviral.2018.09.015. Epub 2018 Oct 1.

PMID:
30287226
9.

5'-Hydroxy-5'-homoaristeromycin: Synthesis and antiviral properties.

Chen Q, Liu C, Bowlin TL, Schneller SW.

Bioorg Med Chem Lett. 2018 May 15;28(9):1456-1458. doi: 10.1016/j.bmcl.2018.03.088. Epub 2018 Mar 31.

PMID:
29628328
10.

Aminomethyl Spectinomycins as Therapeutics for Drug-Resistant Gonorrhea and Chlamydia Coinfections.

Butler MM, Waidyarachchi SL, Connolly KL, Jerse AE, Chai W, Lee RE, Kohlhoff SA, Shinabarger DL, Bowlin TL.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00325-18. doi: 10.1128/AAC.00325-18. Print 2018 May.

11.

Impact of Type III Secretion Effectors and of Phenoxyacetamide Inhibitors of Type III Secretion on Abscess Formation in a Mouse Model of Pseudomonas aeruginosa Infection.

Berube BJ, Murphy KR, Torhan MC, Bowlin NO, Williams JD, Bowlin TL, Moir DT, Hauser AR.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01202-17. doi: 10.1128/AAC.01202-17. Print 2017 Nov.

12.

Design, Synthesis, and Evaluation of Novel Prodrugs of Transition State Inhibitors of Norovirus 3CL Protease.

Galasiti Kankanamalage AC, Kim Y, Rathnayake AD, Alliston KR, Butler MM, Cardinale SC, Bowlin TL, Groutas WC, Chang KO.

J Med Chem. 2017 Jul 27;60(14):6239-6248. doi: 10.1021/acs.jmedchem.7b00497. Epub 2017 Jul 11.

PMID:
28671827
13.

Molecular Mechanism Underlying the Action of Influenza A Virus Fusion Inhibitor MBX2546.

Basu A, Komazin-Meredith G, McCarthy C, Antanasijevic A, Cardinale SC, Mishra RK, Barnard DL, Caffrey M, Rong L, Bowlin TL.

ACS Infect Dis. 2017 May 12;3(5):330-335. doi: 10.1021/acsinfecdis.6b00194. Epub 2017 Apr 3.

14.

A Sensitive in Vitro High-Throughput Screen To Identify Pan-filoviral Replication Inhibitors Targeting the VP35-NP Interface.

Liu G, Nash PJ, Johnson B, Pietzsch C, Ilagan MX, Bukreyev A, Basler CF, Bowlin TL, Moir DT, Leung DW, Amarasinghe GK.

ACS Infect Dis. 2017 Mar 10;3(3):190-198. doi: 10.1021/acsinfecdis.6b00209. Epub 2017 Feb 9.

15.

Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models.

Robertson GT, Scherman MS, Bruhn DF, Liu J, Hastings C, McNeil MR, Butler MM, Bowlin TL, Lee RB, Lee RE, Lenaerts AJ.

J Antimicrob Chemother. 2017 Mar 1;72(3):770-777. doi: 10.1093/jac/dkw467.

16.

DNA Targeting as a Likely Mechanism Underlying the Antibacterial Activity of Synthetic Bis-Indole Antibiotics.

Opperman TJ, Kwasny SM, Li JB, Lewis MA, Aiello D, Williams JD, Peet NP, Moir DT, Bowlin TL, Long EC.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7067-7076. Print 2016 Dec.

17.

Potency and Stereoselectivity of Cyclopropavir Triphosphate Action on Human Cytomegalovirus DNA Polymerase.

Chen H, Li C, Zemlicka J, Gentry BG, Bowlin TL, Coen DM.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4176-82. doi: 10.1128/AAC.00449-16. Print 2016 Jul.

18.

Molecular basis for inhibition of AcrB multidrug efflux pump by novel and powerful pyranopyridine derivatives.

Sjuts H, Vargiu AV, Kwasny SM, Nguyen ST, Kim HS, Ding X, Ornik AR, Ruggerone P, Bowlin TL, Nikaido H, Pos KM, Opperman TJ.

Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):3509-14. doi: 10.1073/pnas.1602472113. Epub 2016 Mar 14.

19.

Application of virus-like particles (VLP) to NMR characterization of viral membrane protein interactions.

Antanasijevic A, Kingsley C, Basu A, Bowlin TL, Rong L, Caffrey M.

J Biomol NMR. 2016 Mar;64(3):255-65. doi: 10.1007/s10858-016-0025-1. Epub 2016 Feb 26.

20.

Synthesis and antifungal evaluation of head-to-head and head-to-tail bisamidine compounds.

Nguyen ST, Kwasny SM, Ding X, Williams JD, Peet NP, Bowlin TL, Opperman TJ.

Bioorg Med Chem. 2015 Sep 1;23(17):5789-98. doi: 10.1016/j.bmc.2015.07.006. Epub 2015 Jul 14.

21.

Novel Small Molecule Entry Inhibitors of Ebola Virus.

Basu A, Mills DM, Mitchell D, Ndungo E, Williams JD, Herbert AS, Dye JM, Moir DT, Chandran K, Patterson JL, Rong L, Bowlin TL.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S425-34. doi: 10.1093/infdis/jiv223. Epub 2015 Jul 22.

22.

Discovery of bacterial fatty acid synthase type II inhibitors using a novel cellular bioluminescent reporter assay.

Wallace J, Bowlin NO, Mills DM, Saenkham P, Kwasny SM, Opperman TJ, Williams JD, Rock CO, Bowlin TL, Moir DT.

Antimicrob Agents Chemother. 2015 Sep;59(9):5775-87. doi: 10.1128/AAC.00686-15. Epub 2015 Jul 13.

23.

TAOK3 phosphorylates the methylenecyclopropane nucleoside MBX 2168 to its monophosphate.

Komazin-Meredith G, Cardinale SC, Comeau K, Magalhaes KJ, Hartline CB, Williams JD, Opperman TJ, Prichard MN, Bowlin TL.

Antiviral Res. 2015 Jul;119:23-7. doi: 10.1016/j.antiviral.2015.04.001. Epub 2015 Apr 7.

24.

Structure-activity relationships of a novel pyranopyridine series of Gram-negative bacterial efflux pump inhibitors.

Nguyen ST, Kwasny SM, Ding X, Cardinale SC, McCarthy CT, Kim HS, Nikaido H, Peet NP, Williams JD, Bowlin TL, Opperman TJ.

Bioorg Med Chem. 2015 May 1;23(9):2024-34. doi: 10.1016/j.bmc.2015.03.016. Epub 2015 Mar 13.

25.

Synthesis and structure-activity relationships of novel phenoxyacetamide inhibitors of the Pseudomonas aeruginosa type III secretion system (T3SS).

Williams JD, Torhan MC, Neelagiri VR, Brown C, Bowlin NO, Di M, McCarthy CT, Aiello D, Peet NP, Bowlin TL, Moir DT.

Bioorg Med Chem. 2015 Mar 1;23(5):1027-43. doi: 10.1016/j.bmc.2015.01.011. Epub 2015 Jan 13.

26.

Synthesis and antiviral activities of 3-deaza-3-fluoroaristeromycin and its 5' analogues.

Chen Q, Liu C, Komazin G, Bowlin TL, Schneller SW.

Bioorg Med Chem. 2014 Dec 15;22(24):6961-4. doi: 10.1016/j.bmc.2014.10.014. Epub 2014 Nov 6.

PMID:
25456389
27.

Synthesis and antibacterial evaluation of new, unsymmetrical triaryl bisamidine compounds.

Nguyen ST, Williams JD, Butler MM, Ding X, Mills DM, Tashjian TF, Panchal RG, Weir SK, Moon C, Kim HO, Marsden JA, Peet NP, Bowlin TL.

Bioorg Med Chem Lett. 2014 Aug 1;24(15):3366-72. doi: 10.1016/j.bmcl.2014.05.094. Epub 2014 Jun 12.

28.

Mutagenesis studies of the H5 influenza hemagglutinin stem loop region.

Antanasijevic A, Basu A, Bowlin TL, Mishra RK, Rong L, Caffrey M.

J Biol Chem. 2014 Aug 8;289(32):22237-45. doi: 10.1074/jbc.M114.572974. Epub 2014 Jun 19.

29.

Mutations in the Pseudomonas aeruginosa needle protein gene pscF confer resistance to phenoxyacetamide inhibitors of the type III secretion system.

Bowlin NO, Williams JD, Knoten CA, Torhan MC, Tashjian TF, Li B, Aiello D, Mecsas J, Hauser AR, Peet NP, Bowlin TL, Moir DT.

Antimicrob Agents Chemother. 2014;58(4):2211-20. doi: 10.1128/AAC.02795-13. Epub 2014 Jan 27.

30.

Cytomegalovirus mutants resistant to ganciclovir and cidofovir differ in susceptibilities to synguanol and its 6-ether and 6-thioether derivatives.

Chou S, Komazin-Meredith G, Williams JD, Bowlin TL.

Antimicrob Agents Chemother. 2014;58(3):1809-12. doi: 10.1128/AAC.02544-13. Epub 2013 Dec 30.

31.

Small molecule inhibitors of anthrax lethal factor toxin.

Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP.

Bioorg Med Chem. 2014 Jan 1;22(1):419-34. doi: 10.1016/j.bmc.2013.11.009. Epub 2013 Nov 13.

32.

Characterization of a novel pyranopyridine inhibitor of the AcrAB efflux pump of Escherichia coli.

Opperman TJ, Kwasny SM, Kim HS, Nguyen ST, Houseweart C, D'Souza S, Walker GC, Peet NP, Nikaido H, Bowlin TL.

Antimicrob Agents Chemother. 2014;58(2):722-33. doi: 10.1128/AAC.01866-13. Epub 2013 Nov 18.

33.

Potent and broad-spectrum antibacterial activity of indole-based bisamidine antibiotics: synthesis and SAR of novel analogs of MBX 1066 and MBX 1090.

Williams JD, Nguyen ST, Gu S, Ding X, Butler MM, Tashjian TF, Opperman TJ, Panchal RG, Bavari S, Peet NP, Moir DT, Bowlin TL.

Bioorg Med Chem. 2013 Dec 15;21(24):7790-806. doi: 10.1016/j.bmc.2013.10.014. Epub 2013 Oct 25.

34.

New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusion.

Basu A, Antanasijevic A, Wang M, Li B, Mills DM, Ames JA, Nash PJ, Williams JD, Peet NP, Moir DT, Prichard MN, Keith KA, Barnard DL, Caffrey M, Rong L, Bowlin TL.

J Virol. 2014 Feb;88(3):1447-60. doi: 10.1128/JVI.01225-13. Epub 2013 Nov 6.

35.

Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions.

Komazin-Meredith G, Chou S, Prichard MN, Hartline CB, Cardinale SC, Comeau K, Williams JD, Khan AR, Peet NP, Bowlin TL.

Antimicrob Agents Chemother. 2014;58(1):274-8. doi: 10.1128/AAC.01726-13. Epub 2013 Oct 21.

36.

Human herpesvirus 6 U69 kinase phosphorylates the methylenecyclopropane nucleosides cyclopropavir, MBX 2168, and MBX 1616 to their monophosphates.

Komazin-Meredith G, Cardinale SC, Williams JD, Peet NP, Prichard MN, Bowlin TL.

Antimicrob Agents Chemother. 2013 Nov;57(11):5760-2. doi: 10.1128/AAC.00978-13. Epub 2013 Aug 26.

37.

Characterization of the Burkholderia thailandensis SOS response by using whole-transcriptome shotgun sequencing.

Ulrich RL, Deshazer D, Kenny TA, Ulrich MP, Moravusova A, Opperman T, Bavari S, Bowlin TL, Moir DT, Panchal RG.

Appl Environ Microbiol. 2013 Oct;79(19):5830-43. doi: 10.1128/AEM.00538-13. Epub 2013 Jul 19.

38.

Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses.

Prichard MN, Williams JD, Komazin-Meredith G, Khan AR, Price NB, Jefferson GM, Harden EA, Hartline CB, Peet NP, Bowlin TL.

Antimicrob Agents Chemother. 2013 Aug;57(8):3518-27. doi: 10.1128/AAC.00429-13. Epub 2013 May 13.

39.

Optimization of a novel potent and selective bacterial DNA helicase inhibitor scaffold from a high throughput screening hit.

Li B, Pai R, Aiello D, Di M, Barnes MH, Peet NP, Bowlin TL, Moir DT.

Bioorg Med Chem Lett. 2013 Jun 15;23(12):3481-6. doi: 10.1016/j.bmcl.2013.04.055. Epub 2013 Apr 30.

40.

Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance.

Chou S, Ercolani RJ, Marousek G, Bowlin TL.

Antimicrob Agents Chemother. 2013 Jul;57(7):3375-9. doi: 10.1128/AAC.00511-13. Epub 2013 May 6.

41.

Coumarin-based inhibitors of Bacillus anthracis and Staphylococcus aureus replicative DNA helicase: chemical optimization, biological evaluation, and antibacterial activities.

Li B, Pai R, Di M, Aiello D, Barnes MH, Butler MM, Tashjian TF, Peet NP, Bowlin TL, Moir DT.

J Med Chem. 2012 Dec 27;55(24):10896-908. doi: 10.1021/jm300922h. Epub 2012 Dec 11.

42.

Bis-imidazolinylindoles are active against methicillin-resistant Staphylococcus aureus and multidrug-resistant Mycobacterium tuberculosis.

Panchal RG, Lane D, Boshoff HI, Butler MM, Moir DT, Bowlin TL, Bavari S.

J Antibiot (Tokyo). 2013 Jan;66(1):47-9. doi: 10.1038/ja.2012.93. Epub 2012 Nov 14. No abstract available.

PMID:
23149517
43.

Solute restriction reveals an essential role for clag3-associated channels in malaria parasite nutrient acquisition.

Pillai AD, Nguitragool W, Lyko B, Dolinta K, Butler MM, Nguyen ST, Peet NP, Bowlin TL, Desai SA.

Mol Pharmacol. 2012 Dec;82(6):1104-14. doi: 10.1124/mol.112.081224. Epub 2012 Sep 4.

44.

New classes of antibiotics.

Moir DT, Opperman TJ, Butler MM, Bowlin TL.

Curr Opin Pharmacol. 2012 Oct;12(5):535-44. doi: 10.1016/j.coph.2012.07.004. Epub 2012 Jul 26. Review.

PMID:
22841284
45.

MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile.

Butler MM, Shinabarger DL, Citron DM, Kelly CP, Dvoskin S, Wright GE, Feng H, Tzipori S, Bowlin TL.

Antimicrob Agents Chemother. 2012 Sep;56(9):4786-92. doi: 10.1128/AAC.00508-12. Epub 2012 Jun 25.

46.

Synthesis and antiviral activity of certain second generation methylenecyclopropane nucleosides.

Williams JD, Khan AR, Harden EA, Hartline CB, Jefferson GM, Keith KA, Prichard MN, Zemlicka J, Peet NP, Bowlin TL.

Bioorg Med Chem. 2012 Jun 15;20(12):3710-8. doi: 10.1016/j.bmc.2012.04.049. Epub 2012 May 1.

47.

Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.

Li B, Cardinale SC, Butler MM, Pai R, Nuss JE, Peet NP, Bavari S, Bowlin TL.

Bioorg Med Chem. 2011 Dec 15;19(24):7338-48. doi: 10.1016/j.bmc.2011.10.062. Epub 2011 Oct 26.

48.

Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure.

Chou S, Marousek G, Bowlin TL.

Antimicrob Agents Chemother. 2012 Jan;56(1):197-201. doi: 10.1128/AAC.05559-11. Epub 2011 Oct 3.

49.

High-throughput screening of viral entry inhibitors using pseudotyped virus.

Basu A, Mills DM, Bowlin TL.

Curr Protoc Pharmacol. 2010 Dec;Chapter 13:Unit 13B.3. doi: 10.1002/0471141755.ph13b03s51.

PMID:
21935898
50.

Preparation and antibacterial evaluation of decarboxylated fluoroquinolones.

Nguyen ST, Ding X, Butler MM, Tashjian TF, Peet NP, Bowlin TL.

Bioorg Med Chem Lett. 2011 Oct 1;21(19):5961-3. doi: 10.1016/j.bmcl.2011.07.060. Epub 2011 Jul 29.

PMID:
21865042

Supplemental Content

Loading ...
Support Center